SCHEMBL7981548

SCHEMBL7981548

O=C(O)N1CCc2cc(F)ccc21

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 5/20 0.73
CNR2 P34972 1/20 0.59
CDK4 P11802 1/20 0.53
CCND1 P24385 1/20 0.53
PDK1 Q15118 1/20 0.50
PDK2 Q15119 1/20 0.50
PDK3 Q15120 1/20 0.50
PDK4 Q16654 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
GAA P10253 1/20 0.49
HTT P42858 1/20 0.49
CYP11B2 P19099 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
STAT1 P42224 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4108434 0.86 NOTUM (0.55) NOTUMCNR2GAAHTTNPC1
SCHEMBL30930563 0.85 NOTUM (0.71) NOTUMCNR2CDK4CCND1PDK1
SCHEMBL31465710 0.85 NOTUM (0.71) NOTUMCNR2CDK4CCND1PDK1
SCHEMBL2205988 0.85 NOTUM (1.00) NOTUMCNR2CDK4CCND1CYP11B2
SCHEMBL26691279 0.85 NOTUM (0.71) NOTUMCNR2CDK4CCND1PDK1
SCHEMBL7814158 0.82 NOTUM (0.65) NOTUMCNR2GAAALDH1A1KDM4E
SCHEMBL853846 0.79 PDK1 (0.50) NOTUMPDK1PDK2PDK3PDK4
SCHEMBL3971068 0.79 NOTUM (0.73) NOTUMCDK4CCND1HDAC1HDAC6
SCHEMBL288802 0.79 SLC22A12 (0.59) NOTUMPDK1PDK2PDK3PDK4
SCHEMBL15690093 0.79 NOTUM (0.49) NOTUMCNR2CYP11B2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6274594-B1 ANTICONVULSANTS, ANALGESICS; NERUOPATHIC, CANCER AND DENTAL PAIN; SMITHKLINE BEECHAM P.L.C. (GB) 2001-08-14 US claimed
US-9546162-B2 Compounds and methods for skin repair ALLERGAN, INC. (US) 2017-01-17 US disclosed
EP-3049392-A1 COMPOUNDS AND METHODS FOR SKIN REPAIR ALLERGAN, INC. (US) 2016-08-03 EP disclosed
WO-2015048553-A1 COMPOUNDS AND METHODS FOR SKIN REPAIR ALLERGAN, INC. (US) 2015-04-02 WO disclosed
US-20150094330-A1 COMPOUNDS AND METHODS FOR SKIN REPAIR ALLERGAN INC (US) 2015-04-02 US disclosed
US-6274594-B1 ANTICONVULSANTS, ANALGESICS; NERUOPATHIC, CANCER AND DENTAL PAIN; SMITHKLINE BEECHAM P.L.C. (GB) 2001-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150094330-A1 COMPOUNDS AND METHODS FOR SKIN REPAIR PTGER4, LTB4R2, LTB4R NOTUM 1966/4885CNR2 97/4885CDK4 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.